GlassScriptPhysician profile
William Charles Warren
NPI 1487915716
$5,202.31
in general payments reported to CMS, 2019-2025
28 companies · $718 in 2025
The $718 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $661 · 2022: $1,684 · 2023: $1,110 · 2024: $1,029 · 2025: $718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,857.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,857.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,106.15 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $613.55 | 2021-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $457.03 | 2021-2025 | Tremfya, Stelara |
| Qol Medical, LLC | $390.63 | 2021-2025 | Sucraid, Sucraid |
| Celgene Corporation | $258.88 | 2021-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $183.23 | 2022-2024 | Entyvio |
| Pfizer INC. | $148.71 | 2021-2025 | |
| Ipsen Biopharmaceuticals, INC | $120.26 | 2024-2025 | Iqirvo, Bylvay |
| Ardelyx, INC. | $117.46 | 2022-2025 | Ibsrela |
| Braintree Laboratories, INC. | $108.86 | 2021-2022 | |
| Genzyme Corporation | $108.36 | 2022-2025 | |
| Gilead Sciences, INC. | $70.61 | 2021-2022 | |
| Amgen INC. | $58.46 | 2023 | Avsola, Amjevita |
| Apollo Endosurgery US INC | $48.08 | 2022-2023 | Overstitch Endoscopic Suturing System |
| Phathom Pharmaceuticals, INC. | $46.63 | 2024 | Voquezna |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Echosens North America, INC. | $42.06 | 2024 | Fibroscan |
| Ironwood Pharmaceuticals, INC | $41.84 | 2023 | Linzess |
| Aimmune Therapeutics, INC. | $35.36 | 2025 | Vowst |
| Intra-Sana Laboratories | $35.25 | 2022-2023 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Organon LLC | $30.09 | 2022 | |
| Merck Sharp & Dohme LLC | $28.11 | 2022 | |
| Nestle Healthcare Nutrition INC. | $27.79 | 2022-2023 | |
| Daiichi Sankyo INC. | $27.50 | 2024 | Injectafer |
| Intercept Pharmaceuticals, INC. | $22.57 | 2023 | Ocaliva |
| Lilly USA, LLC | $22.08 | 2025 | Omvoh |
| Novo Nordisk INC | $19.75 | 2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $18.98 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $14.03 | 2024 | Sancuso |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Warren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.